Abstract 18235: Treatment of Small Vessel Disease (<2.5mm) With a Placlitaxel Eluting Balloon: 6 Months Outcomes of the Spanish Multicenter Registry

Backgroung: Independently of the type of percutaneous coronary intervention (balloon angioplasty and/or stenting with BMS/DES): coronary vessel size (small) is a strong predictor for restenosis following angioplasty, representing a challenging problem even in the DES era. We sought to assess the efficacy and safety of a new placlitaxel-coated, drug-eluting balloon (DEB) in patients with small vessel disease. Methods: 89 patients and 91 de novo significant native coronary lesions in small vessel (<2.5mm), treated by using a new paclitaxel-eluting balloon (3.0μg/m2 balloon surface area) were included in this prospective multicenter (11 Spanish center) registry. In each case, after optimal dilatation using conventional balloon angioplasty, a DEB was inflated for a minimum of 60 seconds. Clinical follow-up was planned at 1, 6 and 12 months with repeat angiography at 6–8 months in 50%. DAT was recommended at standard doses for at least 1 month. The only exclusion criteria were acute MI and cardiogenic shock. R...